Browse: Departments   Dates   Agencies  

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Docket ID: [Docket No. FDA-2006-E-0440] (formerly Docket No. 2006E-0483)

NOTICE: NOTICES

DOCUMENT ACTION: Notice.

SUBJECT CATEGORY: Determination of Regulatory Review Period for Purposes of Patent Extension; ERAXIS

DOCUMENT SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for ERAXIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

SUMMARY: Determination of Regulatory Review Period for Purposes of Patent Extension; ERAXIS,

SUPPLEMENTAL INFORMATION

The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the human drug product becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Director of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product, ERAXIS (anidulafungin). ERAXIS is indicated for treatment of the following fungal infections: Candidemia and other forms of Candida infections (intraabdominal abscess and peritonitis), and esophageal candidiasis. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for ERAXIS (U.S. Patent No. 5,965,525) from Eli Lilly and Co., and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated February 6, 2007, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of ERAXIS represented the first permitted commercial marketing or use of the product. Thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for ERAXIS is 3,476 days. Of this time, 2,446 days occurred during the testing phase of the regulatory review period, while 1,030 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(i)) became effective: August 14, 1996. The applicant claims July 15, 1996, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was August 14, 1996, which was 30 days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the act: April 25, 2003. The applicant claims August 18, 2005, as the date the new drug application (NDA) 21948 for ERAXIS was initially submitted. However, FDA records indicate that NDA 21948 was not the first NDA for anidulafungin submitted to the agency by Vicuron Pharmaceuticals, Inc., the owner of the applications at the time of submission. NDA 21632, Vicuron's first NDA for anidulafungin, was submitted on April 25, 2003.

3. The date the application was approved: February 17, 2006. FDA has verified the applicant's claim that NDA 21948 was approved on February 17, 2006. NDA 21632 was also approved on February 17, 2006.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,224 days of patent term extension.

Anyone with knowledge that any of the dates as published are incorrect may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments and ask for a redetermination by August 22, 2008. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by December 22, 2008. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 4142, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Division of Dockets Management. Three copies of any mailed information are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Please note that on January 15, 2008, the FDA Division of Dockets Management Web site transitioned to the Federal Dockets Management System (FDMS). FDMS is a Governmentwide, electronic docket management system. Electronic comments or submissions will be accepted by FDA only through FDMS at http://www.regulations.gov.

Dated: June 9, 2008.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research. [FR Doc. E814156 Filed 62008; 8:45 am]
BILLING CODE 416001S

FOR FURTHER INFORMATION CONTACT Beverly Friedman, Office of Regulatory Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51,
[[Page 35403]]
rm. 6222, Silver Spring, MD 209930002, 3017963602.